CJC-1295 no DAC 5mg

CJC-1295 no DAC (also written as CJC-1295 (No DAC) or Mod GRF(1–29)) is a growth hormone–releasing hormone (GHRH) analogue used for in-vitro studies of GHRH receptor signalling, cAMP/PKA pathways, and GH-axis models under controlled, non-clinical conditions.

CJC-1295 (No DAC)

This listing refers to the non-DAC (short, Mod GRF(1–29)) variant, which researchers select to probe ligand–receptor engagement, second-messenger dynamics, and structure–activity relationships in cell systems.
For laboratory research only. Not for human use.

CJC-1295 Key features

• Non-DAC GHRH analogue (Mod GRF(1–29)) for in-vitro studies of GHRHR signalling and GH-axis biology.
• Supplied as a lyophilised solid for stability and straightforward storage.
• Unit size: 5 mg per vial.
• Each batch released only after stringent quality checks.

Specifications

• Product name: CJC-1295 (No DAC) / Mod GRF(1–29)
• Synonyms: CJC-1295 no DAC; Mod GRF(1–29); tetrasubstituted GRF(1–29)
• Class: Growth hormone–releasing hormone analogue (non-DAC)
• Form: Lyophilised powder
• Appearance: White to off-white solid
• Note: Exact properties may vary by counter-ion/hydration state

Handling & storage

1. Storage (dry): Keep vials protected from light and moisture.
2. Reconstitution: Bring vial and diluent to room temperature. Reconstitute with
   Bacteriostatic Water 10 ml. Swirl gently — do not vortex.
3. After reconstitution: Store at 2–8 °C, protect from light, use aliquots to reduce handling, and avoid repeated temperature cycling.
4. Compatibility: Use only within research protocols that follow your lab’s SOPs and local regulations.

Looking for complementary materials? See
Bacteriostatic Water 10 ml and GH-axis research companions such as
Ipamorelin 5 mg and
GHRP-6 5 mg.

About CJC-1295 (No DAC) in research

Researchers employ the non-DAC variant to map GHRHR binding and downstream signalling, including cAMP accumulation, PKA activation, and related transcriptional responses. Studies focus on receptor pharmacology and pathway profiling exclusively in controlled, non-clinical in-vitro environments.

Synthesis & quality

Manufactured via controlled, validated peptide-synthesis processes to deliver high purity and lot-to-lot consistency. Each batch undergoes identity, purity, and appearance checks before release.